Morniflu Bambini (Morniflumate)

Morniflumate blocks cyclooxygenase enzymes (COX‑1 and COX‑2), which are essential for producing prostaglandins. By lowering prostaglandin levels, the drug diminishes inflammation, pain signaling, and fever at the site of tissue injury.

The exact dose and frequency of Morniflu Bambini are determined by the prescribing clinician based on the child's age, weight, and clinical condition. Patients should follow the prescriber’s instructions and not alter the regimen without medical advice.

Safety of Morniflu Bambini in pregnancy or lactation has not been established. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Morniflu Bambini belongs to the fenamate subclass of NSAIDs, which tend to have a slightly different COX inhibition profile compared with ibuprofen or naproxen. Its rectal formulation offers a convenient route for children who cannot swallow tablets, but the overall efficacy and safety are comparable to other NSAIDs when used appropriately.

Store Morniflu Bambini at ambient temperature, preferably below 25 °C. Keep the suppositories in their original packaging, protect them from moisture and direct sunlight, and ensure they are out of reach of children.

Morniflu Bambini is administered rectally. The suppository is gently inserted into the rectum, preferably after a bowel movement, using clean hands or a disposable applicator. Follow the prescriber’s instructions regarding timing and frequency.

Serious risks include severe allergic reactions such as anaphylaxis, Stevens‑Johnson syndrome, gastrointestinal bleeding or ulcer perforation, and hepatic or renal impairment. Patients should seek immediate medical attention if they experience symptoms like rash, swelling, difficulty breathing, vomiting blood, or dark urine.

Morniflu Bambini should be avoided in children with known hypersensitivity to Morniflumate or other fenamate NSAIDs, active peptic ulcer disease, severe renal or hepatic impairment, and in those receiving anticoagulant therapy unless closely monitored by a physician.